First human trial begins for dual-target Alzheimer's vaccine

This early study will test the safety and immune response of a new Alzheimer's vaccine called DUVAX in 24 healthy adults aged 40-65. Participants will receive either the vaccine or a placebo injection to see how well it's tolerated and whether it produces antibodies against Alzheimer's-related proteins. The main goal is to check for side effects and measure the body's immune reaction over one year.